70078 Federal Register / Vol. 70, No. 223 / Monday, November 21, 2005 / Notices 

retardation, lifespan-extension, and 

organ procurement for transplantation. 

Publications issued by the Council to 

date include: Human Cloning and 

Human Dignity: An Ethical Inquiry (July 

2002); Beyond Therapy: Biotechnology 

and the Pursuit of Happiness (October 

2003); Being Human: Readings from the 

President’s Council on Bioethics 

(December 2003); Monitoring Stem Cell 

Research (January 2004), Reproduction 

and Responsibility: The Regulation of 

New Biotechnologies (March 2004), 

Alternative Sources of Human 

Pluripotent Stem Cells: A White Paper 

(May 2005), and Taking Care: Ethical 

Caregiving in Our Aging Society 

(September 2005). 

DATES: The meeting will take place 

Thursday, December 8, 2005, from 9 

a.m. to 4:30 p.m. ET; and Friday, 

December 9, 2005, from 8:30 a.m. to 

12:30 p.m. ET. 

ADDRESSES: City Center Hotel, 1143 

New Hampshire Avenue, NW., 

Washington, DC 20037. Phone 202–775–

0800. 

Agenda: The meeting agenda will be 

posted at http://www.bioethics.gov. 

Public Comments: The Council 

encourages public input, either in 

person or in writing. At this meeting, 

interested members of the public may 

address the Council, beginning at 11:30 

a.m., on Friday, December 9. Comments 

are limited to no more than five minutes 

per speaker or organization. As a 

courtesy, please inform Ms. Diane 

Gianelli, Director of Communications, 

in advance of your intention to make a 

public statement, and give your name 

and affiliation. To submit a written 

statement, mail or e-mail it to Ms. 

Gianelli at one of the addresses given 

below. 

FOR FURTHER INFORMATION CONTACT: Ms. 

Diane Gianelli, Director of 

Communications, The President’s 

Council on Bioethics, Suite 700, 1801 

Pennsylvania Avenue, Washington, DC 

20006. Telephone: 202/296–4669. Email: info@bioethics.gov. Web site: 

http://www.bioethics.gov. 

Dated: November 16, 2005. 

Richard Roblin, 

Acting Executive Director, The President’s 

Council on Bioethics. 

[FR Doc. 05–22990 Filed 11–18–05; 8:45 am] 

BILLING CODE 4154–06–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Fees for Sanitation Inspections of 

Cruise Ships 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice. 

SUMMARY: This notice announces an 

increase in the fees for vessel sanitation 

inspections for the remainder of fiscal 

year 2006 (January 1, 2006, through 

September 30, 2006). 

DATES: Effective January 1, 2006. 

FOR FURTHER INFORMATION CONTACT: 

David L. Forney, Chief, Vessel 

Sanitation Program, National Center for 

Environmental Health, Centers for 

Disease Control and Prevention (CDC), 

4770 Buford Highway, NE., Mailstop F–

23, Atlanta, Georgia 30341–3724, 

telephone (770) 488–7333, E-mail: 

Dforney@cdc.gov. 

SUPPLEMENTARY INFORMATION: 

Purpose and Background 

The fee schedule for sanitation 

inspections of passenger cruise ships 

inspected under the Vessel Sanitation 

Program (VSP) was first published in 

the Federal Register on November 24, 

1987, (52 FR 45019), and CDC began 

collecting fees on March 1, 1988. Since 

1987, CDC has published the fee 

schedule annually. The fees schedule 

for FY 2006 was initially announced in 

the Federal Register on September 7, 

2005, with fees effective October 1, 

2005. Because of a significant increase 

in travel expenses and personnel costs, 

VSP will be increasing inspection fees 

effective January 1, 2006. This will be 

the first increase in fees since FY 2002. 

The formula used to determine the 

fees is as follows: 

Average cost per inspection = Total cost of VSP

Weighted number of annual inspections

The average cost per inspection is 

multiplied by a size/cost factor to 

determine the fee for vessels in each 

size category. The size/cost factor was 

established in the proposed fee schedule 

published in the Federal Register on 

July 17, 1987, (52 FR 27060) and revised 

in a schedule published in the Federal 

Register on November 28, 1989, (54 FR 

48942). The revised size/cost factor is 

presented in Appendix A. 

Fee 

The fee schedule (Appendix A) will 

be effective January 1, 2006, through 

September 30, 2006. If travel expenses 

continue to increase, the fees may need 

adjustment before September 30, 2006, 

because travel constitutes a sizable 

portion of VSP’s costs. If an adjustment 

is necessary, a notice will be published 

in the Federal Register 30 days before 

the effective date. 

Applicability 

The fees will apply to all passenger 

cruise vessels for which inspections are 

conducted as part of CDC’s VSP. 

Dated: November 7, 2005. 

Carlton Duncan, 

Deputy Chief Operating Officer, Office of the 

Director, Centers for Disease Control and 

Prevention (CDC). 

Appendix A 

SIZE/COST FACTOR

Vessel size GRT 1 Average cost 

($U.S.) per GRT 

Extra Small .................................................................................................................................................. <3,001 0.25 

Small ............................................................................................................................................................ 3,001–15,000 0.50 

Medium ........................................................................................................................................................ 15,001–30,000 1.00 

Large ............................................................................................................................................................ 30,001–60,000 1.50 

Extra Large .................................................................................................................................................. >60,000 2.00 

1Gross register tonnage in cubic feet, as shown in Lloyd’s Register of Shipping. 


EN21NO05.079</MATH>
Federal Register / Vol. 70, No. 223 / Monday, November 21, 2005 / Notices 70079 

FEE SCHEDULE JANUARY 1, 2006–SEPTEMBER 30, 2006 

Vessel size GRT 1 Fee 

Extra Small .................................................................................................................................................. <3,001 1,300 

Small ............................................................................................................................................................ 3,001–15,000 2,600 

Medium ........................................................................................................................................................ 15,001–30,000 5,200 

Large ............................................................................................................................................................ 30,001–60,000 7,800 

Extra Large .................................................................................................................................................. >60,000 10,400 

1Gross register tonnage in cubic feet, as shown in Lloyd’s Register of Shipping. 

Inspections and reinspections involve the 

same procedure, require the same amount of 

time, and are therefore charged at the same 

rate. 

[FR Doc. 05–22967 Filed 11–18–05; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

Notice of Approval of Supplemental 

New Animal Drug Application; 

Ivermectin and Praziquantel Paste 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is providing 

notice that it has approved a 

supplemental new animal drug 

application (NADA) filed by Merial, Ltd. 

The NADA provides for oral use of an 

ivermectin and praziquantel paste as an 

over-the-counter product for the 

treatment and control of various 

parasitic conditions of horses. This 

supplemental NADA reduces the 

minimum age for administration from 5 

months to 2 months of age. 

FOR FURTHER INFORMATION CONTACT: 

Melanie R. Berson, Center for Veterinary 

Medicine (HFV–110), Food and Drug 

Administration, 7500 Standish Pl., 

Rockville, MD 20855, 301–827–7543, email: melanie.berson@fda.gov. 

SUPPLEMENTARY INFORMATION: Merial, 

Ltd., 3239 Satellite Blvd., bldg. 500, 

Duluth, GA 30096–4640, filed a 

supplement to NADA 141–214 for 

ZIMECTERIN GOLD (ivermectin 1.55%/ 

praziquantel 7.75%) Paste, an over-thecounter product used for the oral 

treatment and control of various 

parasitic conditions of horses. This 

supplemental NADA reduces the 

minimum age for administration from 5 

months to 2 months of age. In 

accordance with section 512(i) of the 

Federal Food, Drug, and Cosmetic Act 

(the act) (21 U.S.C. 360b(i)) and part 514 

(21 CFR part 514) in §§ 514.105(a) and 

514.106(a), the Center for Veterinary 

Medicine is providing notice that this 

supplemental NADA is approved as of 

October 28, 2005. The basis of approval 

is discussed in the freedom of 

information summary. 

In accordance with the freedom of 

information provisions of 21 CFR part 

20 and § 514.11(e)(2)(ii), a summary of 

safety and effectiveness data and 

information submitted to support 

approval of this application may be seen 

in the Division of Dockets Management 

(HFA–305), Food and Drug 

Administration, 5630 Fishers Lane, rm. 

1061, Rockville, MD 20852, between 9 

a.m. and 4 p.m., Monday through 

Friday. 

FDA has determined under 21 CFR 

25.33(d)(1) that this action is of a type 

that does not individually or 

cumulatively have a significant effect on 

the human environment. Therefore, 

neither an environmental assessment 

nor an environmental impact statement 

is required. 

Dated: November 7, 2005. 

Steven D. Vaughn, 

Director, Office of New Animal Drug 

Evaluation, Center for Veterinary Medicine. 

[FR Doc. 05–22941 Filed 11–18–05; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Eye Institute; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Eye Institute 

Special Emphasis Panel, Gene Therapy 

Clinical Trial. 

Date: November 21, 2005. 

Time: 1 p.m. to 2 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Sheraton Gateway Hotel Los Angeles 

Airport, 6101 W Century Blvd., Los Angeles, 

CA 90045. 

Contact Person: Samuel Rawlings, PhD, 

Chief, Scientific Review Branch, Division of 

Extramural Research, National Eye Institute, 

5635 Fishers Lane, Suite 1300, MSC 9300, 

Bethesda, MD 20892–9300, 301–451–2020. 

(Catalogue of Federal Domestic 

Assistance Program No. 93.867, Vision 

Research, National Institutes of Health, 

HHS) 

Dated: November 14, 2005. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 05–22932 Filed 11–18–05; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of a meeting of the 

Board of Scientific Counselors, NHLBI. 

The meeting will be closed to the 

public as indicated below in accordance 

with the provisions set forth in section 

552b(c)(6), Title 5 U.S.C., as amended 

for the review, discussion, and 

evaluation of individual grant 

applications conducted by the National 

Heart, Lung, and Blood Institute, 

including consideration of personnel 

qualifications and performance, and the 

competence of individual investigators, 

the disclosure of which would 

constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Board of Scientific 

Counselors, NHLBI.